ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / SYRE
MDGL (38) PTGX (65) TGTX (63) BMRN (74) ⌘ Pro Terminal →

Spyre Therapeutics Inc. (SYRE) — RQD Stock Rating Cockpit

$95.51 -1.09% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $95.14

Spyre Therapeutics Inc. (SYRE) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $10.08B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SYRE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SYRE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Spyre Therapeutics Inc. (NASDAQ: SYRE) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $95.51 (-1.09% 1D, market cap $10.08B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, SYRE ranks #202 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SYRE compare to MDGL and PTGX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SYRE carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -20.0%. By comparison, MDGL (Madrigal Pharmaceuticals Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -29.7%, cap $9.94B) and PTGX (Protagonist Therapeutics Inc.) posts a C grade (65/100 RQD, P/E N/A, ROIC -16.7%, cap $9.37B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SYRE?
▼

Per SYRE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001636282), Spyre Therapeutics Inc. generated $586.8M in revenue (+0.5% YoY), -$155.2M in net income, and -$169.3M in free cash flow against $777.8M in total assets and $28.1M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $95.14 (-0.39%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY • 51.4% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510055
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D · Rk C+
Cash (5)Whales (17)SEC (16)Macro (11)CEO (6)
Each axis scored 0–20
12M PRICE TARGET CONE-1.4% Base Target
$116 Bull$94 Base$73 Bear
📬 FREE SYRE RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SYRE)Realized 20D OHLCV Swing Band: ±9.6%
Deterministic 5-Pillar Attribution (55/100 Composite)
🔍 WHY SYRE SCORES 55/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (31% of score)

20D Institutional Volume Accumulation (±9.6% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (29% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Cash Engine Quality5/20 pts (-15 pt drag)

Capital intensity & 0% operating margin leave 15 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
47
Grade D$78.63+18.2% Next Q
Q2 (-2Q)
50
Grade C-$92.95+7.3% Next Q
Q3 (-1Q)
52
Grade C-$99.75-4.3% Next Q
Current
55
Grade D+$95.51-0.5% Hist 90D α
Trajectory: D (47) → D+ (55)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the SYRE Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 55/100 (D+) score, SYRE faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Dilution Drag (+1.64% YoY Shares) — any gross margin slip below 15.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($89.54) or 200D SMA ($74.19) invalidates the momentum regime and cuts Target Base ($94.22) toward Bear Floor ($73.49).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SYRE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SYRE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 55%NO 45%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
57.330 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
26.00>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
5 / 99-Pt Accounting
52-WEEK LASER RANGE84% OF RANGE
L: $21$95.51H: $110
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: D+RQD 23 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C+RQD 27 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

Quant Analyst Panel Split (Battleground) on SYRE

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (25)

-20.0% ROIC with 42.0% gross margin and -1.64% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (80)

Altman-Z 26.00 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
NEUTRAL (57)

23/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like SYRE
  • ✓Big institutional funds and options desks are actively positioning on the bullish side.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SYRE)

  • ✓Walkthrough of SYRE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SYRE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +38.16%📐 WEDGE COMPRESSION COIL
2026-11-03O $98.96H $98.96L $95.51C $95.51VOL 661.2K
RES: $99.64SUP: $78.53SMA50: $89.54SMA200: $74.19
$115.7$92.87$70.05$47.23$24.41RES $99.64SUP $78.53$95.512026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SYRE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SYRE Butterfly Map → + Track SYRE →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
15.7%/yr Implied 5Y Growth

vs. +0.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SYRE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SYRE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SYRE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SYRE)

Health Care Rank #202 of 1015 ⚔️ MDGL vs SYRE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SYRE vs. MDGL, PTGX, TGTX, BMRN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Spyre Therapeutics Inc. (SYRE) ranks #202 by composite RQD confidence (55/100, grade D+) and #108 by equity capitalization ($10.08B). Within this direct 5-issuer industry benchmark cohort, TGTX leads on earnings valuation at 19.9x trailing P/E, while TGTX leads on capital efficiency and profitability with 12.0% ROIC and 83.7% gross margin. BMRN currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with SYRE at 55/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SYRE ACTIVE
Spyre Therapeutics Inc.
D+ 55/100 — — -20.0% -1.09% $10.08B Benchmark Subject
MDGL
Madrigal Pharmaceuticals Inc.
D- 38/100 — — -29.7% +0.19% $9.94B /mdgl-vs-syre →
PTGX
Protagonist Therapeutics Inc.
C 65/100 — — -16.7% -3.78% $9.37B /ptgx-vs-syre →
TGTX
TG Therapeutics Inc.
C 63/100 19.9x 83.7% 12.0% -2.01% $9.36B /tgtx-vs-syre →
BMRN
BioMarin Pharmaceutical Inc.
B 74/100 31.9x 77.7% 6.0% -1.83% $11.33B /bmrn-vs-syre →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001636282 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Spyre Therapeutics Inc. (SYRE) reported GAAP revenue of $586.8M (+0.5% vs. FY2024 revenue of $584.0M , and +66127.3% cumulative change since FY2023) , GAAP net income of -$155.2M, operating cash flow of -$169.3M, and free cash flow of -$169.3M (-7.5% YoY). On the balance sheet, SYRE closed FY2025 with $777.8M in total assets against $28.1M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $586.8M -$155.2M -$169.3M -$169.3M $777.8M $28.1M
FY2024 (FY) 2024-12-31 $584.0M -$208.0M -$157.4M -$157.4M $608.5M $40.8M
FY2023 (FY) 2023-12-31 $886.0K -$338.8M -$99.9M -$99.9M $5.68B $1.33B

3. SYRE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SYRE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Spyre Therapeutics Inc. (NASDAQ: SYRE) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $95.51 (-1.09% 1D, market cap $10.08B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, SYRE ranks #202 in composite RQD confidence.

How does SYRE compare to MDGL and PTGX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SYRE carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -20.0%. By comparison, MDGL (Madrigal Pharmaceuticals Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -29.7%, cap $9.94B) and PTGX (Protagonist Therapeutics Inc.) posts a C grade (65/100 RQD, P/E N/A, ROIC -16.7%, cap $9.37B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SYRE?

Per SYRE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001636282), Spyre Therapeutics Inc. generated $586.8M in revenue (+0.5% YoY), -$155.2M in net income, and -$169.3M in free cash flow against $777.8M in total assets and $28.1M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SYRE trading relative to its 50-day, 200-day, and 52-week technical levels?

SYRE last traded at $95.51 (-1.09% on volume of 752,115 shares), positioning the stock +6.67% above its 50-day simple moving average ($89.54) and +28.74% above its 200-day simple moving average ($74.19). Across its 52-week range of $21.15 to $110.18, SYRE sits at the 83.5% percentile with a 14-day RSI of 57.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±9.6% ($86.34 to $104.68).

Direct Sub-Reports: SYRE RQD Cockpit SYRE 12M Forecast SYRE Earnings & Move SYRE Dividends & DRIP SYRE Insiders & 13F SYRE Whale Options SYRE Profit Sankey SYRE News & Why
ROARABLE RATING BRIEF • RQD 55/100 (D+) ✓ SEC XBRL & RQD VERIFIED

SYRE — Spyre Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Spyre Therapeutics Inc. (SYRE) earns a live Roarable RQD composite score of 55/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $95.51 (-1.09% 1D, market capitalization $10.08B).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -20.0%, gross margin of —, operating margin of —, and free cash flow yield of -1.64%.
  • Whale 13F & Options Flow (17/20) + Insider Conviction (6/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (16/20): Incorporates a 0.89x equity beta, Altman Z-Score of 26.00, Piotroski F-Score of 5/9, and Debt/Equity of 0.04x.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations. Reported revenue is — for FY 2025 and FY 2024, and $0.9M for FY 2023, .

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Spyre Therapeutics Inc. (SYRE) reported $586.8M in annual revenue (up from $584.0M in FY2024, +0.5% YoY) and -$155.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($886.0K revenue, -$338.8M net income) through FY2025, SYRE scaled operating cash flow to -$169.3M and free cash flow to -$169.3M, backed by $777.8M in total assets against $28.1M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 55/100): Big institutional funds and options desks are actively positioning on the bullish side. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 17/20, sustained execution supports upside toward the upper end of the $21.15 – $110.18 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 0.89x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

There are no upstream or downstream links, no supply-chain designation, and no proprietary signals. Sector correlations and second-order bottlenecks are — The only related catalyst is the public offering noted in the news feed, which may dilute existing holders; the source does not quantify the offering size or terms.

  • Key Question #1: Can SYRE sustain or expand its — operating margin and -20.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $586.8M and free cash flow of -$169.3M, how will capital allocation balance growth reinvestment against $28.1M in total debt?
  • Key Question #3: How sensitive is SYRE's 22.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.89x)?

SYRE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Spyre Therapeutics Inc. (SYRE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SYRE Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SYRE Bull vs. Bear Conversation Board — What's Your Call at $95.51?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SYRE 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SYRE:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $119.73 (+24.0%)
📌 Pinned Debate

Institutional accumulation and options positioning score 17/20 while Debt/Equity of 0.04 and an Altman Z of 26 indicate minimal balance

Here is why I am bullish on SYRE here at $96.56: Institutional accumulation and options positioning score 17/20 while Debt/Equity of 0.04 and an Altman Z of 26 indicate minimal balance-sheet stress.. Compare SYRE's 0.0% operating margin and -20.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $91.73 are getting bought.

RetailWhale_TX 🐂 BULL

Both sides have a point here — SYRE's 16/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $83.04 (-14.0%)
Spot @ $96.56

ROIC of -20%, FCF yield of -1.64%, and a pending public offering signal that current operations are not self-funding and may dilute sha

Careful chasing SYRE at $96.56. ROIC of -20%, FCF yield of -1.64%, and a pending public offering signal that current operations are not self-funding and may dilute shareholders.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $83.04 on multiple compression.

LIVE TAPE